Benitec Biopharma Ltd ADR (BNTC) - Total Assets
Based on the latest financial reports, Benitec Biopharma Ltd ADR (BNTC) holds total assets worth $190.68 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Benitec Biopharma Ltd ADR to assess how comfortably operating cash covers total debt obligations.
Benitec Biopharma Ltd ADR - Total Assets Trend (2013–2025)
This chart illustrates how Benitec Biopharma Ltd ADR's total assets have evolved over time, based on quarterly financial data. See BNTC net assets for net asset value and shareholders' equity analysis.
Benitec Biopharma Ltd ADR - Asset Composition Analysis
Current Asset Composition (June 2025)
Benitec Biopharma Ltd ADR's total assets of $190.68 Million consist of 98.9% current assets and 1.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 98.1% |
| Accounts Receivable | $33.00K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Benitec Biopharma Ltd ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BNTC market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Benitec Biopharma Ltd ADR's current assets represent 98.9% of total assets in 2025, a decrease from 99.9% in 2013.
- Cash Position: Cash and equivalents constituted 98.1% of total assets in 2025, up from 90.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 0.0% of total assets.
Benitec Biopharma Ltd ADR Competitors by Total Assets
Key competitors of Benitec Biopharma Ltd ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
Benitec Biopharma Ltd ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 67.69 | 25.48 | 5.08 |
| Quick Ratio | 67.69 | 25.48 | 5.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $186.79 Million | $75.62 Million | $9.96 Million |
Benitec Biopharma Ltd ADR - Advanced Valuation Insights
This section examines the relationship between Benitec Biopharma Ltd ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.26 |
| Latest Market Cap to Assets Ratio | 4.22 |
| Asset Growth Rate (YoY) | 90.8% |
| Total Assets | $99.59 Million |
| Market Capitalization | $420.65 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Benitec Biopharma Ltd ADR's assets at a significant premium (4.22x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Benitec Biopharma Ltd ADR's assets grew by 90.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Benitec Biopharma Ltd ADR (2013–2025)
The table below shows the annual total assets of Benitec Biopharma Ltd ADR from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $99.59 Million | +90.75% |
| 2024-06-30 | $52.21 Million | +1069.58% |
| 2023-06-30 | $4.46 Million | -25.26% |
| 2022-06-30 | $5.97 Million | -72.06% |
| 2021-06-30 | $21.38 Million | +82.04% |
| 2020-06-30 | $11.74 Million | -38.86% |
| 2019-06-30 | $19.21 Million | +22.53% |
| 2018-06-30 | $15.68 Million | -10.00% |
| 2017-06-30 | $17.42 Million | +17.26% |
| 2016-06-30 | $14.85 Million | -24.12% |
| 2015-06-30 | $19.57 Million | -18.53% |
| 2014-06-30 | $24.03 Million | -23.68% |
| 2013-06-30 | $31.48 Million | -- |
About Benitec Biopharma Ltd ADR
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single a… Read more